Bladder chemodenervation (Botox)

Phase 1Small molecule

Bladder chemodenervation (Botox) is one of 4 small molecule programs targeting Spinal Cord Injuries. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Cord InjuriesEnrolling by invitation

Spinal Cord InjuriesPhase 1

Enrolling by invitation

Competition

Competitive Landscape

3 competitors in Spinal Cord Injuries

#DrugCompanyPhaseTrials

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 2

Lioresal

Novartis

Preclinical

1 3

Zanaflex

LLegacy Health System

Preclinical

1 4

Bladder chemodenervation (Botox)

UUniversity of Washington

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spinal Cord Injuries1 trial

Early Detrusor Chemodenervation to Preserve Bladder Compliance and Longevity After Spinal Cord Injury

Enrolling by invitation·UUniversity of Washington·Phase 1·NCT06793683·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bladder chemodenervation (Botox). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bladder chemodenervation (Botox) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bladder chemodenervation (Botox). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Washington

Bladder chemodenervation (Botox)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spinal Cord Injuries1 trial

References

Drug Info

Quick Facts

Related News